Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease

Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135.
No abstract available

Publication types

  • Published Erratum